focus -WSS

focus

author：focus 2025-09-28 13:25:59 - browse：795

The Food and Drug Administration on Tuesday approved brexanolone, the first drug specifically targeted to treat postpartum depression — the most common complication of childbirth. Yet it’s a condition that often goes untreated because new mothers fear being stigmatized if they report symptoms.

Brexanolone is the first drug developed by and approved from Sage Therapeutics. The Cambridge, Mass.-based biotech company will market the new medicine under the brand name Zulresso.

“This approval is important for postpartum depression patients and it’s important for our company. It’s rare in your career when you can introduce a new medicine that is different from what’s out there,” said Sage CEO Jeff Jonas.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： It's been 20 years since Dolly the sheep. Where's my clone?

WSS

Second xenotransplant done with gene

Emergency workers more likely to restrain Black patients: study

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

It's been 20 years since Dolly the sheep. Where's my clone?

Drug for rare kidney disease narrowly misses mark in clinical trial

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

focus

focus

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

Second xenotransplant done with gene

United colonoscopy coverage change 'may cost lives,' doctors say

Wearables generate powerful data but its not useful to doctors, yet

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Emergency workers more likely to restrain Black patients: study

Alkermes shareholders re

CDC advisers recommend seasonal use of Pfizer RSV shot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Changes to biosimilar regulatory framework must prioritize patients

hotspot

Cytokinetics CEO stresses company can launch heart drug on its own

Microbiome research is starting to find links to chronic diseases

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Medical student insurance fails on mental health care coverage

hotspot

leisure time

entertainment

focus